被撤回的出版物: Clazosentan, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury (Retracted article. See vol. 39, pg. 472, 2017)

Objectives: The purpose of this study was to test the efficacy of a novel endothelin receptor A antagonist on blood flow and behavioral outcome given 30 minutes following traumatic brain injury. Methods: Male Sprague-Dawley rats (400-450 g) were used in this study. All animals were scanned for initial blood flow using arterial spin labeling magnetic resonance imaging (n=72 total). Half were subjected to traumatic brain injury using a weight acceleration impact device (n=36 total). Sham operated animals were used as control (n=36 total). Thirty minutes following traumatic brain injury, animals were given one intravenous injection of vehicle (0.9% saline) or 1.0 mg/kg clazosentan, a novel endothelin receptor A antagonist, for a total of four groups. At 4, 24, and 48 hours post-traumatic brain injury, blood flow determination continued. On the second day post-traumatic brain injury/sham operation, behavioral testing commenced using a radial arm maze to assess cognitive function. Results: Our results indicate that 1.0 mg/kg clazosentan was effective in ameliorating hypoperfusion seen after traumatic brain injury. Saline had no effect. Furthermore, clazosentan treatment was effective in significantly improving behavioral outcome following traumatic brain injury. Conclusion: Collectively, these results indicate that clazosentan, given at 30 minutes post-traumatic brain injury, is effective in improving outcome following injury.